Regeneron Pharmaceuticals (REGN) : Traders are bullish on Regeneron Pharmaceuticals (REGN) as it has outperformed the S&P 500 by a wide margin of 3.16% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.73%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.3% in the last 1 week, and is up 1.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.06% and the 50-Day Moving Average is 1.71%.The 200 Day SMA reached 1.47% Regeneron Pharmaceuticals, Inc. is up 15.36% in the last 3-month period. Year-to-Date the stock performance stands at -24.73%.
Regeneron Pharmaceuticals (REGN) has been rated by 16 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $668 and the lowest price target forecast is $325. The average forecast of all the analysts is $475.19 and the expected standard deviation is $83.66.
For the current week, the company shares have a recommendation consensus of Buy. Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened at $403.75 and touched an intraday high of $411 on Friday. During the day, the stock corrected to an intraday low of $400.37, however, the bulls stepped in and pushed the price higher to close in the green at $408.63 with a gain of 1.46% for the day. The total traded volume for the day was 1,311,812. The stock had closed at $408.63 in the previous trading session.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.